Benralizumab‐resistant mucus plugs in severe asthma complicated by eosinophilic chronic rhinosinusitis

Key message It is an absolute necessity to achieve complete control of comorbidities to obtain optimal asthma control. Importantly, type 2 asthma and ECRS share the same inflammatory pathophysiology and are common co‐morbidities. If the initial biologic is insufficiently effective, it is worth consi...

Full description

Saved in:
Bibliographic Details
Published inRespirology case reports Vol. 12; no. 8; pp. e70009 - n/a
Main Authors Hamakawa, Masamitsu, Ishida, Tadashi
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.08.2024
John Wiley & Sons, Inc
Wiley
Subjects
Asthma
benralizumab
Clinical Image
dupilumab
mucus plug
nasal polyp
asthma
mucus plug
benralizumab
nasal polyp
dupilumab
Online AccessGet full text

Cover

More Information
Summary:Key message It is an absolute necessity to achieve complete control of comorbidities to obtain optimal asthma control. Importantly, type 2 asthma and ECRS share the same inflammatory pathophysiology and are common co‐morbidities. If the initial biologic is insufficiently effective, it is worth considering an alternative biologic. This case illustrates that it is an absolute necessity to achieve complete control of comorbidities to obtain optimal asthma control. Importantly, type 2 asthma and eosinophilic chronic rhinosinusitis (ECRS) share the same inflammatory pathophysiology and are common co‐morbidities. If the initial biologic is insufficiently effective to control asthma, it is worth considering an alternative biologic.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Associate Editor: Francesca Gonnelli
ISSN:2051-3380
2051-3380
DOI:10.1002/rcr2.70009